Antiviral Drugs - Uzbekistan

Uzbekistan

The revenue in Uzbekistan's Antiviral Drugs market is expected to reach US$12.31m by 2024.
It is projected to show an annual growth rate (CAGR 2024-2029) of 4.50%, resulting in a market volume of US$15.34m by 2029.
In comparison to other countries, United States is anticipated to generate the highest revenue of US$30,640.00m in 2024.
The demand for antiviral drugs in Uzbekistan has surged due to the increasing prevalence of viral infections in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have become increasingly important in the healthcare industry in recent years. Uzbekistan, a country in Central Asia, has also witnessed a surge in demand for antiviral drugs.

Customer preferences: The customers in Uzbekistan prefer antiviral drugs that have been approved by the country's regulatory authorities. They also tend to opt for drugs that have minimal side effects and are affordable.

Trends in the market: One of the major trends in the antiviral drugs market in Uzbekistan is the increasing prevalence of viral diseases. This has led to a rise in demand for antiviral drugs. The COVID-19 pandemic has also contributed to the growth of the market. The government's efforts to control the spread of the virus have led to an increase in the production and distribution of antiviral drugs.

Local special circumstances: Uzbekistan has a well-established pharmaceutical industry that produces a range of medicines, including antiviral drugs. The country has also implemented various initiatives to promote the local production of drugs. This has led to an increase in the availability of antiviral drugs in the country.

Underlying macroeconomic factors: The growth of the antiviral drugs market in Uzbekistan can be attributed to several underlying macroeconomic factors. The country has a large population, which has led to an increase in demand for healthcare services. The government has also invested heavily in the healthcare sector, which has led to an improvement in the quality of healthcare services. Additionally, the country's stable economic growth has led to an increase in disposable income, which has made healthcare services more accessible to the general population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.